Historical idxx News Stories
IDEXX: FX & Clinic Strain; CAG Growth Drives Stock
IDEXX is navigating currency headwinds and U.S. clinic staffing shortages that are weighing on pockets of its business, while Companion Animal Group diagnostics and cloud services continue to drive outsized growth. Recent institutional trimming and insider sales add a near-term sentiment signal for investors.
IDEXX Slides After Rally; Cancer Dx Fuels Growth!!
IDEXX (NASDAQ: IDXX) saw a notable pullback after a strong 2025 run-up and an IBD spotlight. Recent price weakness on January 20 contrasts with underlying operational momentum—new product rollouts (Cancer Dx), instrument placements, and raised guidance that continue to support the diagnostics growth story for companion animals.
IDEXX Soars After IBD Spotlight, Q1 Results RiseUp
IDEXX (IDXX) gained fresh momentum after Investor’s Business Daily named it Stock of the Day and the company issued recent quarterly results. Technical strength, analyst conviction, and upcoming earnings/guidance are the primary drivers investors should monitor.
IDEXX Upgrades, Product Wins, Insider Sale Impact.
Analyst price-target upgrades and new diagnostics products boost IDEXX sentiment, while an EVP insider sale invites scrutiny. No material events reported this week.
IDEXX Surges After Strong Q2, Raised 2025 Guidance
IDEXX Laboratories (IDXX) reported stronger-than-expected Q2 results with double-digit revenue growth, record instrument placements of nearly 2,400 inVue Dx units, and an upward revision to full-year 2025 revenue and EPS guidance. FX tailwinds and recurring consumables tied to diagnostics drove the upgrade. This article explains the drivers, investor implications, and what to watch next.
IDEXX Q4 Beat Software Fuels Growth Despite Visits
IDEXX (IDXX) posted a fourth-quarter beat driven by diagnostic demand and strong software adoption. Adjusted EPS of $2.62 topped estimates and revenue of $954.3M exceeded expectations, highlighting recurring-revenue resilience despite weaker veterinary clinic visits. This article breaks down the numbers, the operational drivers, investor implications, and near-term risks.
IDEXX Q3 Surge: InVue Placements Drive Growth Now!
IDEXX posted a robust Q3 with $1.105B revenue, raised full-year guidance, and accelerated inVue Dx placements—driving durable recurring revenue across companion animal, livestock and water testing services. Institutional inflows and product momentum underpin near-term investor confidence.
IDEXX Dip: 9% Pullback, Fundamentals Still Strong!
IDEXX (IDXX) retreated about 8–9% from its November peak amid low-volume profit-taking this week. Company fundamentals — Q3 revenue growth, recurring diagnostics, and in-clinic innovation — remain intact, leaving the pullback largely technical.
IDEXX Soars: Diagnostics + Software Drive Rally Q4
IDEXX Laboratories (IDXX) extended its strong 2025 run this week as investors cheered robust diagnostic consumables and accelerating adoption of software tools like Vello and PIMS integrations. YTD gains near 76% reflect concrete growth levers—recurring companion-animal diagnostics revenue, higher utilization from installed instruments, and expanding recurring software bookings—while peers such as Zoetis showed relative weakness. This article summarizes the key data points from the past week, explains why they matter for IDXX’s outlook, and highlights operational and investor considerations.
IDEXX Q3 Beat Lifts Water & Livestock Testing Now!
IDEXX reported strong Q3 2025 results with $1.105B revenue, raised full-year guidance, and notable strength in livestock and water testing; Zoetis’ weaker print contrasts the diagnostic-driven momentum, reinforcing IDEXX’s differentiated exposure in veterinary testing.
IDEXX Q3 Beat, Guidance Up — Dip = Buying Chance!!
IDEXX reported a strong Q3 with 13% revenue growth, raised full‑year guidance and recorded a surge in instrument placements—yet the stock pulled back modestly. Contrast with Zoetis' livestock weakness suggests IDEXX's diagnostics exposure could be a durable advantage. This article breaks down the numbers, market reaction, and investor takeaways.
IDEXX Surge: InVue Install Boom, Catalyst Cortisol
IDEXX reported a sharp uptick in InVue Dx installations and raised guidance after strong quarterly results; new Catalyst Cortisol testing and multiple analyst price-target increases have reinforced investor confidence in IDXX’s diagnostic growth trajectory.
IDEXX Surge: Cancer Dx Launch, Analyst Upside Now!!
IDEXX’s recent week saw the launch of an affordable Cancer Dx canine lymphoma panel and several analyst upgrades, boosting sentiment. Offsetting this are FX headwinds, rising costs and cooling trading volume — key factors investors should watch.